- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Cyclophosphamide, Fludarabine, Fludarabine Phosphate
- Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 3,016
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia
- Interventions
- asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, idarubicin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine, vincristine sulfate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 2,078 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 32
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 24 more
- Conditions
- Multiple Myeloma
- Interventions
- Thalidomide, Dexamethasone, Cytoxan, Etoposide, Cisplatin, G-CSF
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2005
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Pleomorphic Rhabdomyosarcoma, Stage IIB Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7
- Interventions
- Epirubicin Hydrochloride, External Beam Radiation Therapy, Ifosfamide, Laboratory Biomarker Analysis, Sorafenib Tosylate, Therapeutic Conventional Surgery
- Drug · Radiation · Other + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Breast Cancer
- Interventions
- allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide
- Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Osteosarcoma
- Interventions
- Ifosfamide, Carboplatin, Doxorubicin, Limb Sparing
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • St Louis, Missouri • Memphis, Tennessee
- Conditions
- Rhabdomyosarcoma
- Interventions
- Vincristine, Cyclophosphamide, Vinorelbine, Actinomycin D, Cyclophosphamide Pill
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Hartford, Connecticut + 15 more
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI)
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 45 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome
- Interventions
- Biospecimen Collection, Busulfan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Emapalumab, Fludarabine, Hematopoietic Cell Transplantation, Melphalan, Multigated Acquisition Scan, Mycophenolate Mofetil, Questionnaire Administration, Tacrolimus
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Breast Neoplasms
- Interventions
- Docetaxel, Doxorubicin, Carboplatin, Cyclophosphamide, Trastuzumab, Bevacizumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Multiple Myeloma
- Interventions
- recombinant interferon alfa, carmustine, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, prednisone, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 899 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2006
- U.S. locations
- 34
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 25 more
- Conditions
- Severe Aplastic Anemia
- Interventions
- cyclosporine, Matched Unrelated Donor Hematopoetic Stem Cell Transplant, horse anti-thymocyte globulin (ATG), rabbit anti-thymocyte globulin (ATG), Methotrexate, Fludarabine, Cyclophosphamide, low-dose total body irradiation (TBI), Immunosuppressive Therapy (IST)
- Drug · Procedure · Radiation
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 0 Years to 25 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more
- Conditions
- Pancreatic Cancer
- Interventions
- Cyclophosphamide, GVAX Pancreas Vaccine, Stereotactic Body Radiation, FOLFIRINOX
- Drug · Biological · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Metastatic Melanoma
- Interventions
- Melanoma Reactive TIL, Cyclophosphamide, IL-2, Fludarabine, 1200 total body irradiation (TBI)
- Biological · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Wiskott-Aldrich Syndrome
- Interventions
- Hematopoietic stem cell transplantation, Miltenyi CliniMACS selection system, Fludarabine, Melphalan, Thiotepa
- Procedure · Device · Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 18 Years · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
- Interventions
- bendamustine hydrochloride, dexamethasone, filgrastim, leukapheresis, laboratory biomarker analysis, flow cytometry, etoposide
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Carcinosarcoma, Recurrent Female Reproductive System Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Carcinosarcoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinosarcoma, Refractory Fallopian Tube Carcinoma, Refractory Female Reproductive System Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
- Interventions
- Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
- Biological · Drug · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Lymphoma, Hodgkin Disease, Lymphoma, Hodgkin Disease, Lymphoma: Hodgkin
- Interventions
- Vincristine, Cyclophosphamide, Doxorubicin, Prednisone, Bleomycin, Etoposide, Low-dose radiotherapy (RT)
- Drug · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2017
- U.S. locations
- 2
- States / cities
- Stanford, California • Vallejo, California
- Conditions
- Multiple Myeloma
- Interventions
- Cilta-cel, Talquetamab, Daratumumab, Teclistamab, Bortezomib, Lenalidomide, Dexamethasone, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 5
- States / cities
- Duarte, California • San Francisco, California • Iowa City, Iowa + 2 more
- Conditions
- Mature B-Cell Lymphoma
- Interventions
- COPAD, COP, COPD M3, CYM, COP, COPADM8, CYVE
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2027
- U.S. locations
- 2
- States / cities
- San Diego, California • Memphis, Tennessee
- Conditions
- Recurrent Melanoma, Stage IV Melanoma
- Interventions
- therapeutic autologous lymphocytes, aldesleukin, cyclophosphamide, biopsy, immunohistochemistry staining method, flow cytometry, polymerase chain reaction
- Biological · Drug · Procedure + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Bendamustine, Rituximab, Acalabrutinib, Cytarabine, Leukapheresis, Peripheral blood, Oral rinse, Bone marrow collection
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Prostate Cancer
- Interventions
- docetaxel, estramustine phosphate sodium, thalidomide
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer
- Interventions
- epoetin alfa, filgrastim, cyclophosphamide, doxorubicin hydrochloride, epirubicin hydrochloride, fluorouracil, paclitaxel
- Biological · Drug
- Lead sponsor
- NCIC Clinical Trials Group
- Network
- Eligibility
- Up to 60 Years · Female only
- Enrollment
- 2,104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2014
- U.S. locations
- 44
- States / cities
- Fort Smith, Arkansas • Little Rock, Arkansas • La Jolla, California + 39 more